Garrett M. Frampton

Histone H3K27ac separates active from poised enhancers and predicts developmental state

Menno P. Creyghton, Albert W. Cheng, G. Grant Welstead et al. · Proceedings of the National Academy of Sciences · 2010 · 4.5K citations · Full text

Life Sciences, Developmental Biology, Genetics +17

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Zachary R. Chalmers, Caitlin Connelly, David Fabrizio et al. · Genome Medicine · 2017 · 3.7K citations · Full text

Medicine, Cancer Biology, Oncology +17

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles et al. · The Lancet · 2016 · 3.7K citations

Medicine, Oncology, Pharmacotherapy +13

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

Aaron M. Goodman, Shumei Kato, Lyudmila Bazhenova et al. · Molecular Cancer Therapeutics · 2017 · 2.4K citations · Full text

Medicine, Immunology, Oncology +17

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

Garrett M. Frampton, Alex Fichtenholtz, Geoff Otto et al. · Nature Biotechnology · 2013 · 2.2K citations · Full text

Medicine, Genetics, Oncology +14